American Academy of Ophthalmology

Dr. Lally discusses the effect of avacincaptad pegol treatment on the progression of geographic atrophy and intermediate age-related macular degeneration.

Findings from the phase 2 INFINITY suggest a more dose-dependent influence on safety outcomes in patients receiving sustained benefit for diabetic macular edema.

An update from the PIONEER trial shows the combination gene therapy and medical device strategy is safe and tolerable, while providing cases of improved light perception.

Dr. Haller discusses issues in diversity and inclusion in retina, but provides avenues for solutions and what needs to come next.

An AAO 2021 presentation highlighted the industrial design differences that could result in treatment overdoses with pre-filled syringes of aflibercept.

Early 2020 response to the pandemic was linked to many patients being lost to follow-up, and countries reported worse overall visual acuity among their patients.

New HAWK and HARRIER findings show patients with fluid-free visits reported greater benefit in BVCA while receiving anti-VEGF.

A uveitis specialist breaks down what occurs during the uveitis-dedicated event and comments on its importance.

Raymond Douglas, MD, PhD discusses how the COVID-19 pandemic has affected his clinical practice and potentially accelerated technological innovation as a whole.

A post-hoc analysis of the CANTREAT trial finds similar GA frequency, characteristics, and surface area between patients in treat-and-extend and once-monthly regimen cohorts.

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.

A recent study presented at AAO 2020 reports that increased choroid vascular flow was noted in both small and large vessels in patients with non-vitrectomized eyes.

A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.

A new IRIS registry analysis reports that many patients with geographic atrophy do not continue follow-up after initial visit or consultation.

RD surgery and scleral buckle appear to be preferred among ophthalmologists—but are linked to further necessary care in children.

Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.

Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.

A new trial shows treatment-naive patients with nAMD have similar BCVA and safety outcomes with the biosimilar.

For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.

Data show patients can decrease annual injections while retaining, if not improving, on BCVA scores over 104 weeks.

Lynn Hassman, MD, talks about a promising new technology that can optimize precision medicine in patients with uveitis.

New findings suggest the common ophthalmic disorder in premature infants could be three-fold more prevalent in multiracial infants.

In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.

New AAO 2020 findings suggest even geographical differences could define retinal detachment risks among nearsighted patients.

In data presented at AAO, investigators find BI 836680 shows early signals of bioactivity.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

The study presented at AAO provides an update on previously shared 6-month data from earlier this year.

Raymond Douglas, MD, PhD, discusses data that demonstrate the benefit of teprotumumab in patients with all levels of thyroid eye disease.

Edmund Tsui, MD, talks the new AAO 2020 virtual format as well as presentations that have particularly caught his attention.